Table 1.
Characteristics of patients treated with CTNB vs. non-biopsy in the observational dataset and after propensity score matching for patients with p-stage I-III.
| Variables | Observational dataset (n = 1667) | Propensity score-matched dataset (n = 336) | |||||
|---|---|---|---|---|---|---|---|
| CTNB n = 168(%) |
Non-biopsy n = 1499(%) |
p value | CTNB n = 168(%) |
Non-biopsy n = 168(%) |
p value | ||
| Age | 0.858 | 0.323 | |||||
| ≥60 | 79 (47.02) | 694 (46.30) | 79 (47.02) | 70 (41.67) | |||
| <60 | 89 (52.98) | 805 (53.70) | 89 (52.98) | 98 (58.33) | |||
| Gender | 0.511 | 1.000 | |||||
| Male | 90 (53.57) | 763 (50.90) | 90 (53.57) | 90 (53.57) | |||
| Female | 78 (46.43) | 736 (49.10) | 78 (46.43) | 78 (46.43) | |||
| T stage | <0.001* | 0.989 | |||||
| 1 | 45 (26.78) | 691 (46.10) | 45 (26.78) | 46 (27.38) | |||
| 2 | 105 (62.50) | 700 (46.70) | 105 (62.50) | 105 (62.50) | |||
| 3 | 13 (7.74) | 60 (4.00) | 13 (7.74) | 13 (7.74) | |||
| 4 | 5 (2.98) | 48 (3.20) | 5 (2.98) | 4 (2.38) | |||
| N stage | 0.064 | 0.359 | |||||
| 0 | 96 (57.14) | 990 (66.04) | 96 (57.14) | 102 (60.72) | |||
| 1 | 22 (13.10) | 169 (11.28) | 22 (13.10) | 27 (16.07) | |||
| 2 | 50 (29.76) | 340 (22.68) | 50 (29.76) | 39 (23.21) | |||
| TNM stage | <0.001* | 0.145 | |||||
| I | 71 (42.26) | 890 (59.37) | 71 (42.26) | 89 (52.98) | |||
| II | 42 (25.00) | 231 (15.41) | 42 (25.00) | 34 (20.24) | |||
| III | 55 (32.74) | 378 (25.22) | 55 (32.74) | 45 (26.78) | |||
| Location | 0.825 | 0.850 | |||||
| Central | 16 (9.52) | 135 (9.01) | 16 (9.52) | 15 (8.93) | |||
| Peripheral | 152 (90.48) | 1364 (90.99) | 152 (90.48) | 153 (91.07) | |||
| Pathology | <0.001* | 0.991 | |||||
| Ad | 117 (69.64) | 1253 (83.59) | 117 (69.64) | 116 (69.05) | |||
| Scc | 36 (21.43) | 184 (12.27) | 36 (21.43) | 37 (22.02) | |||
| Others | 15 (8.93) | 62 (4.14) | 15 (8.93) | 15 (8.93) | |||
| Chemotherapy# | <0.001* | 1.000 | |||||
| Yes | 87 (51.79) | 465 (31.02) | 87 (51.79) | 87 (51.79) | |||
| No | 81 (48.21) | 1034 (68.98) | 81 (48.21) | 81 (48.21) | |||
| Radiotherapy# | 0.474 | 0.557 | |||||
| Yes | 7 (4.17) | 47 (3.14) | 7 (4.17) | 5 (2.98) | |||
| No | 161 (95.83) | 1452 (96.86) | 161 (95.83) | 163 (97.02) | |||
Abbreviations: CTNB, computed tomography-guided needle biopsy; Ad, adenocarcinoma; Scc: squamous-cell carcinoma.
#: adjuvant therapy. *P < 0.05.